NTLA (Intellia Therapeutics) Total Assets: $758.78 Mil (As of Mar. 2026)


NTLA Intellia Therapeutics Inc NTLA
71 GF Score
Price $17.56
GF Value $20.57
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Intellia Therapeutics Total Assets?

Intellia Therapeutics NTLA +1.89% 71 Total Assets is $758.78 Mil as of Mar. 2026. GuruFocus rates NTLA with a GF Score™ of 71/100 and a GF Value™ of $20.57 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Intellia Therapeutics's Total Assets for the quarter that ended in Mar. 2026 was $758.78 Mil.

During the past 12 months, Intellia Therapeutics's average Total Assets Growth Rate was -20.70% per year. During the past 3 years, the average Total Assets Growth Rate was 6.20% per year. During the past 5 years, the average Total Assets Growth Rate was 27.20% per year. During the past 10 years, the average Total Assets Growth Rate was 53.60% per year.

During the past 12 years, Intellia Therapeutics's highest 3-Year average Total Assets Growth Rate was 247.30%. The lowest was 2.60%. And the median was 70.10%.

Total Assets is connected with ROA %. Intellia Therapeutics's annualized ROA % for the quarter that ended in Mar. 2026 was -48.09%. Total Assets is also linked to Revenue through Asset Turnover. Intellia Therapeutics's Asset Turnover for the quarter that ended in Mar. 2026 was 0.02.

Intellia Therapeutics  (NAS:NTLA) Total Assets Explanation

Total Assets is connected with ROA %.

Intellia Therapeutics's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-384.924/( (842.127+758.779)/ 2 )
=-384.924/800.453
=-48.09 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Intellia Therapeutics's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=15.048/( (842.127+758.779)/ 2 )
=15.048/800.453
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Intellia Therapeutics Total Assets Related Terms

Intellia Therapeutics Total Assets Historical Data

* Premium members only.

The historical data trend for Intellia Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Intellia Therapeutics Total Assets Chart

Intellia Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,294.46 1,520.11 1,300.98 1,191.02 842.13

Intellia Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 986.16 898.89 925.28 842.13 758.78
NTLA
71GF Score
Intellia Therapeutics Inc NTLA
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Intellia Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Intellia Therapeutics's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=671.394+170.733
=842.13

Intellia Therapeutics's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=620.939+137.84
=758.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $758.78 Mil mean?
Intellia Therapeutics (NTLA) has a Total Assets of $758.78 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Intellia Therapeutics and its competitors.
Is Intellia Therapeutics' Total Assets too high?
Intellia Therapeutics' current Total Assets is $758.78 Mil. Overall, Intellia Therapeutics has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Intellia Therapeutics' Total Assets compare to MLYS and VCEL?
Intellia Therapeutics' Total Assets of $758.78 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Intellia Therapeutics and its competitors. Intellia Therapeutics's current Total Assets is $758.78 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intellia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Intellia Therapeutics (NTLA) is currently considered Modestly Undervalued. The stock's GF Value™ is $20.57, compared to a current price of $17.56 — trading 14.6% below its estimated fair value. The current Total Assets is $758.78 Mil. Intellia Therapeutics' overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Intellia Therapeutics (NTLA), the current Total Assets is $758.78 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Intellia Therapeutics (NTLA) Overvalued in 2026?

Based on GuruFocus' analysis, Intellia Therapeutics stock appears to be undervalued. The current stock price of $17.56 is trading 14.6% below its estimated GF Value™ of $20.57. GuruFocus considers Intellia Therapeutics to be Modestly Undervalued.

Key valuation signals for NTLA:

  • Total Assets: $758.78 Mil
  • GF Value™: $20.57 vs. price of $17.56 (14.6% below fair value)
  • GF Score™: 71/100 with 3 warning signs

No single metric tells the full story. See the NTLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Intellia Therapeutics Business Description

Other Exchanges 0JBU:UK38I:Germany
Address 40 Erie Street, Suite 130, Cambridge, MA, USA, 02139
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
71GF Score

Get the complete analysis for NTLA

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.56
Price
$20.57
GF Value